Abstract
Trypanosomatids are protozoan parasites that cause various diseases in human, such as leishmaniasis, Chagas disease and sleeping sickness. The highly syntenic genomes of the trypanosomatid species lead the assumption that they can encode similar proteins, indicating the possibility to design new antitrypanosomatid drugs with dual trypanosomicidal and leishmanicidal activities. In this work a series of compounds (6a-h and 7a-h), containing a semicarbazone scaffold as a peptide mimetic framework, was designed and synthesized. From this series compound 7g (LASSBio-1483) highlighted, showing dual in vitro trypanosomicidal and leishmanicidal activities, with potency similar to the standard drugs nifurtimox and pentamidine. This data, taken together with its good in silico druglikeness profile and its great chemical and plasma stability, make LASSBio-1483 (7g) a new antitrypanosomatid lead-candidate.
Author supplied keywords
Cite
CITATION STYLE
Alves, M. A., De Queiroz, A. C., Alexandre-Moreira, M. S., Varela, J., Cerecetto, H., González, M., … Lima, L. M. (2015). Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 100, 24–33. https://doi.org/10.1016/j.ejmech.2015.05.046
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.